Catalyst brief · Phase 3 readout · 26 days
VALUE: EscharEx (EX-03) in Venous Leg Ulcer (VLU)
MediWound Ltd · $MDWD · built 19 Nov 2026 from 13 sourced facts · open on the radar
Analyst desk
Five AI analysts read the facts below. Each sentence shows the facts it rests on.
Trial design
Base rates
- The historical success rate of Phase 3 programmes in the relevant group is 62.1%, which is an industry average and not a forecast for this trial. F11
- The company's record of keeping dates is that the primary completion date is 2.0 months later than the date first registered for this trial. F10
- The timing model for this trial estimates the primary completion date to be 26 days from 19 Nov 2026, which is in December 2026. F9
- Past result-day moves are not provided, but insider sales and purchases are reported, with 4 unplanned open-market sales and 1 open-market purchase in the last 90 days. F12 F13
Filings
- Nothing the facts support.
The case for
The case against
- The trial's tight timeline, with the primary completion date estimated to be just 26 days from 19 Nov 2026, may not be realistic, potentially leading to delays or incomplete data, and the company has already shown a tendency to push back deadlines, with the current date being 2.0 months later than initially registered. F9 F10
- With 60 sites and only 6 closed, the trial's recruitment and data collection process may be more complex and time-consuming than anticipated, potentially leading to delays or difficulties in meeting the estimated primary completion date. F8 F9
Open questions
- Will the incidence of complete debridement be significantly higher in one study arm than the other?
- Will the results of the VALUE trial align with the historical 62.1% success rate of Phase 3 programmes in the same group?
- Will the trial meet its primary completion date as estimated in December 2026?
6 AI sentences were removed by the fact check.
The facts
The trial
- F1VALUE is a Phase 3 trial of EscharEx (EX-03) in Venous Leg Ulcer (VLU), sponsored by MediWound Ltd (MDWD). source ↗
- F2The trial plans to enrol 216 patients. source ↗
What counts as success
- F3Main goal as written in the registry: Incidence of complete debridement, clinically (visually) assessed after each application. source ↗
- F4Blinding: quadruple blind. source ↗
- F5Allocation: randomised. source ↗
- F6The main goal is measured over: up to 2 weeks. source ↗
- F7Number of study arms: 2. source ↗
When
- F9The registry gives the primary completion date as Dec 2026 (an estimate), which is 26 days from 19 Nov 2026. source ↗
- F10That date is 2.0 months later than the date first registered for this trial (Oct 2026). source ↗
Recruitment
- F8The registry lists 60 sites, of which 6 have closed. source ↗
Base rates
- F11Historically 62.1% of Phase 3 programmes in cardiovascular and metabolic (the group DataCutoff files this trial under) moved on to a regulatory filing (BIO / Informa / QLS study of 2011 to 2020). This is an industry average, not a forecast for this trial.
Money, insiders and FDA
- F12Insiders made 1 open-market purchases in the last 90 days, totalling $7K; the largest was $7K by the Director on 1 Sep 2026.
- F13Insiders made 4 unplanned open-market sales in the last 90 days, totalling $82K.
How this page is made: the facts come straight from the trial registry, SEC filings and FDA records, each with its link. AI analysts may only restate those facts, and any sentence with a number that is not in a cited fact is removed before publishing. How our models work. Dates are company-reported estimates. Information only, not investment or medical advice.